1887

Abstract

Increasing evidence demonstrates unfavourable outcomes in bloodstream infections (BSI) due to the carbapenem-resistant complex (CRAB).

To investigate the differences in risk factors, clinical characteristics and outcomes in patients with complex BSI stratified by carbapenem resistance, a prospective multi-center study was conducted.

Information was collected in a predefined form. A total of 317 cases was included for comparison between CRAB BSI vs. carbapenem-susceptible complex (CSAB) BSI. Among these cases, 229 cases were defined as CRAB BSI and 88 cases as CSAB BSI.

Univariable analysis showed that male gender, underlying neurologic disease, prior carbapenems exposure, intensive care unit (ICU) stay, presence of central venous catheter, endotracheal intubation, tracheotomy, Foley catheter, nasogastric intubation, lower respiratory tract infections and catheter-related infections were more prevalent in CRAB BSI. Only male gender, prior carbapenems exposure and presence of endotracheal intubation persisted as independent risk factors for acquiring CRAB BSI. Patients with CRAB BSI displayed unfavourable outcomes characterized by failure of pathogen clearance, continuous fever, disease aggravation and higher incidence of 30-day all-cause mortality. Multivariate analysis demonstrated carbapenem resistance as an independent risk factor for 30-day all-cause mortality.

Our findings reveal the epidemiological differences between CRAB BSI and CSAB BSI in a Chinese cohort. Our data suggest that carbapenem resistance has a significant impact on mortality for patients with complex BSI, further strengthening the importance of active prevention and control strategies for the spread of CRAB in Chinese hospitals.

Funding
This study was supported by the:
  • Hui Wang , Pfizer
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001222
2020-06-25
2020-08-11
Loading full text...

Full text loading...

/deliver/fulltext/jmm/69/7/949.html?itemId=/content/journal/jmm/10.1099/jmm.0.001222&mimeType=html&fmt=ahah

References

  1. Wang P, McElheny CL, Mettus RT, Shanks RMQ, Doi Y. Contribution of the TetB efflux pump to minocycline susceptibility among carbapenem-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 2017; 61: [CrossRef][PubMed]
    [Google Scholar]
  2. Doi Y, Bonomo RA, Hooper DC, Kaye KS, Johnson JR et al. Gram-Negative bacterial infections: research priorities, accomplishments, and future directions of the antibacterial resistance leadership group. Clin Infect Dis 2017; 64:S30–S35 [CrossRef][PubMed]
    [Google Scholar]
  3. Bassetti M, Righi E, Esposito S, Petrosillo N, Nicolini L. Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol 2008; 3:649–660 [CrossRef][PubMed]
    [Google Scholar]
  4. Li H, Liu F, Zhang Y, Wang X, Zhao C et al. Evolution of carbapenem-resistant Acinetobacter baumannii revealed through whole-genome sequencing and comparative genomic analysis. Antimicrob Agents Chemother 2015; 59:1168–1176 [CrossRef][PubMed]
    [Google Scholar]
  5. Pogue JM, Mann T, Barber KE, Kaye KS. Carbapenem-Resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert Rev Anti Infect Ther 2013; 11:383–393 [CrossRef][PubMed]
    [Google Scholar]
  6. Hu F-P, Guo Y, Zhu D-M, Wang F, Jiang X-F et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin Microbiol Infect 2016; 22 Suppl 1:S9–14 [CrossRef][PubMed]
    [Google Scholar]
  7. Sheng W-H, Liao C-H, Lauderdale T-L, Ko W-C, Chen Y-S et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii . Int J Infect Dis 2010; 14:e764–e769 [CrossRef][PubMed]
    [Google Scholar]
  8. Metan G, Sariguzel F, Sumerkan B. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia . Eur J Intern Med 2009; 20:540–544 [CrossRef][PubMed]
    [Google Scholar]
  9. Kwon KT, Oh WS, Song J-H, Chang H-H, Jung S-I et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia . J Antimicrob Chemother 2007; 59:525–530 [CrossRef][PubMed]
    [Google Scholar]
  10. Chopra T, Marchaim D, Awali RA, Krishna A, Johnson P et al. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrob Agents Chemother 2013; 57:6270–6275 [CrossRef][PubMed]
    [Google Scholar]
  11. Yang S, Sun J, Wu X, Zhang L. Determinants of mortality in patients with nosocomial Acinetobacter baumannii Bacteremia in Southwest China: a five-year case-control study. Can J Infect Dis Med Microbiol 2018; 2018:1–9 [CrossRef][PubMed]
    [Google Scholar]
  12. Balkhair A, Al-Muharrmi Z, Al'Adawi B, Al Busaidi I, Taher HB et al. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: description of a decade-long trend. Int J Infect Dis 2019; 85:10–15 [CrossRef][PubMed]
    [Google Scholar]
  13. Hu F, Guo Y, Yang Y, Zheng Y, Wu S et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis 2019; 38:2275–2281 [CrossRef][PubMed]
    [Google Scholar]
  14. Wang H, Guo P, Sun H, Wang H, Yang Q et al. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. Antimicrob Agents Chemother 2007; 51:4022–4028 [CrossRef][PubMed]
    [Google Scholar]
  15. CLSI Performance Standards for Antimicrobial Susceptibility Testing, 27th ed; approved standard M100S Wayne, PA: Clinical and Laboratory Standards Institute; 2017
    [Google Scholar]
  16. Zhang J, Zhao C, Chen H, Li H, Wang Q et al. A multicenter epidemiology study on the risk factors and clinical outcomes of nosocomial intra-abdominal infections in China: results from the Chinese antimicrobial resistance surveillance of nosocomial infections (cares) 2007-2016. Infect Drug Resist 2018; 11:2311–2319 [CrossRef][PubMed]
    [Google Scholar]
  17. Kuti JL, Wang Q, Chen H, Li H, Wang H et al. Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints. Infect Drug Resist 2018; 11:783–790 [CrossRef][PubMed]
    [Google Scholar]
  18. Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proc 2011; 86:156–167 [CrossRef][PubMed]
    [Google Scholar]
  19. Chusri S, Silpapojakul K, McNeil E, Singkhamanan K, Chongsuvivatwong V. Impact of antibiotic exposure on occurrence of nosocomial carbapenem-resistant Acinetobacter baumannii infection: a case control study. J Infect Chemother 2015; 21:90–95 [CrossRef][PubMed]
    [Google Scholar]
  20. Lee S-O, Kim NJ, Choi S-H, Hyong Kim T, Chung J-W et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004; 48:224–228 [CrossRef][PubMed]
    [Google Scholar]
  21. Lee Y-T, Wang Y-C, Kuo S-C, Chen C-T, Liu C-P et al. Multicenter study of clinical features of breakthrough Acinetobacter bacteremia during carbapenem therapy. Antimicrob Agents Chemother 2017; 61: [CrossRef][PubMed]
    [Google Scholar]
  22. Lee J-Y, Kang C-I, Ko J-H, Lee WJ, Seok H-R et al. Clinical features and risk factors for development of breakthrough gram-negative bacteremia during carbapenem therapy. Antimicrob Agents Chemother 2016; 60:6673–6678 [CrossRef][PubMed]
    [Google Scholar]
  23. Huang S-T, Chiang M-C, Kuo S-C, Lee Y-T, Chiang T-H et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2012; 45:356–362 [CrossRef][PubMed]
    [Google Scholar]
  24. Lemos EV, de la Hoz FP, Alvis N, Einarson TR, Quevedo E et al. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia. Clin Microbiol Infect 2014; 20:174–180 [CrossRef][PubMed]
    [Google Scholar]
  25. Baran G, Erbay A, Bodur H, Ongürü P, Akinci E et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis 2008; 12:16–21 [CrossRef][PubMed]
    [Google Scholar]
  26. Zhou H-Y, Yuan Z, Du Y-P. Prior use of four invasive procedures increases the risk of Acinetobacter baumannii nosocomial bacteremia among patients in intensive care units: a systematic review and meta-analysis. Int J Infect Dis 2014; 22:25–30 [CrossRef][PubMed]
    [Google Scholar]
  27. O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J et al. Summary of recommendations: guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011; 52:1087–1099 [CrossRef][PubMed]
    [Google Scholar]
  28. Kajihara T, Nakamura S, Iwanaga N, Oshima K, Takazono T et al. Clinical characteristics and risk factors of enterococcal infections in Nagasaki, Japan: a retrospective study. BMC Infect Dis 2015; 15:426 [CrossRef][PubMed]
    [Google Scholar]
  29. Sun JD, Huang SF, Yang SS, Pu SL, Zhang CM et al. Impact of carbapenem heteroresistance among clinical isolates of invasive Escherichia coli in Chongqing, southwestern China. Clin Microbiol Infect 2015; 21:e461-410.469.e1–46469 [CrossRef][PubMed]
    [Google Scholar]
  30. Laupland KB, Gregson DB, Church DL, Ross T, Pitout JDD. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect 2008; 14:1041–1047 [CrossRef][PubMed]
    [Google Scholar]
  31. Wu S, Ren S, Zhao H, Jin H, Xv L et al. Risk factors for central venous catheter-related bloodstream infections after gastrointestinal surgery. Am J Infect Control 2017; 45:549–550 [CrossRef][PubMed]
    [Google Scholar]
  32. Ruggieri A, Gagliardi MC, Anticoli S. Sex-Dependent outcome of hepatitis B and C viruses infections: synergy of sex hormones and immune responses?. Front Immunol 2018; 9:2302 [CrossRef][PubMed]
    [Google Scholar]
  33. Xiong H, Carter RA, Leiner IM, Tang Y-W, Chen L et al. Distinct contributions of neutrophils and CCR2+ monocytes to pulmonary clearance of different Klebsiella pneumoniae strains. Infect Immun 2015; 83:3418–3427 [CrossRef][PubMed]
    [Google Scholar]
  34. Ahn D, Peñaloza H, Wang Z, Wickersham M, Parker D et al. Acquired resistance to innate immune clearance promotes Klebsiella pneumoniae ST258 pulmonary infection. JCI Insight 2016; 1:e89704 [CrossRef][PubMed]
    [Google Scholar]
  35. Vázquez-Martínez ER, García-Gómez E, Camacho-Arroyo I, González-Pedrajo B. Sexual dimorphism in bacterial infections. Biol Sex Differ 2018; 9:27 [CrossRef][PubMed]
    [Google Scholar]
  36. Lemos EV, de la Hoz FP, Einarson TR, McGhan WF, Quevedo E et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect 2014; 20:416–423 [CrossRef][PubMed]
    [Google Scholar]
  37. Tal-Jasper R, Katz DE, Amrami N, Ravid D, Avivi D et al. Clinical and epidemiological significance of carbapenem resistance in Acinetobacter baumannii infections. Antimicrob Agents Chemother 2016; 60:3127–3131 [CrossRef][PubMed]
    [Google Scholar]
  38. Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Nanas S et al. Carbapenem-Resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 2010; 38:173–180 [CrossRef][PubMed]
    [Google Scholar]
  39. Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ et al. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother 2011; 55:4844–4849 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001222
Loading
/content/journal/jmm/10.1099/jmm.0.001222
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error